The fastest, most effective, clinical omega-3 protocol for truly personalised support
Omega-3 EPA and DHA – what, when and how much?
Our requirements for omega-3 change throughout the life stages, with structural DHA being most important during infant development, and functional EPA being the dominant fat during childhood and adult life.
Recommended omega-3 intakes are approximately 500mg daily but with less than 40% of the UK’s population achieving this, and with needs dramatically rising as clinical conditions are diagnosed, the use of supplements that provide the health benefits associated with optimal omega-3 levels is increasingly important.
EPA and DHA work together not only to provide synergistic support when both are maintained at optimal levels within our cells, but they also act via different mechanisms to offer different health benefits. Given these differing roles of EPA and DHA in the body, it is important (whether for prevention or treatment for a clinical condition) to focus on increasing intake of the specific long-chain omega-3 responsible for the benefits required. It is for this reason that it is not helpful to simply take a standard omega-3 supplement and expect benefits. Specific ratios and doses of EPA or DHA, depending on the desired health outcome, are now known to be of key importance in the successful outcomes of clinical trials.
Key benefits of Pharmepa
Addressing inflammation with high EPA is a key factor for therapeutic success
It is well established that chronic inflammation is at the heart of most chronic modern conditions; tailoring omega-3 intervention to quickly and effectively address inflammatory regulation is therefore necessary to maximise clinical benefits. EPA plays a unique role in inflammatory regulation as the only fat directly able to reduce, displace and prevent accumulation and conversion of the omega-6 fat arachidonic acid (AA) into its pro-inflammatory eicosanoids. As a result, focusing early intervention on optimising EPA relative to AA is important to quickly and effectively reduce inflammatory load and reduce symptom severity. Once this has been achieved, introducing a small amount of DHA through supplementation (250mg daily is scientifically established as optimal for long-term health) helps to further support total cell health, throughout life, especially for those not consuming wild oily fish regularly.
Personalised dose determines clinical benefits
Ensuring the right dose of omega-3 is taken is another vital factor for omega-3 therapeutic success and one that has been regularly overlooked in existing research. Recent evidence, however, clearly illustrates the need to dose with omega-3s according to an individual’s current baseline levels, also taking account of their body weight. The lack of consistently positive outcomes following research into omega-3 use in a range of health conditions can be attributed to the huge inter-individual variability in response to a ‘one-size-fits-all’ dosing strategy.
For this reason we recommend using the Igennus Opti-O-3 fatty acid profiling service in combination with Pharmepa RESTORE and MAINTAIN to truly optimise and personalise treatment plans. The Opti-O-3 service identifies the full fatty acid composition of the red blood cells together with the very well established omega-3 biomarkers: the AA to EPA ratio – an accurate marker of inflammatory health status; the omega-3 index – the sum of EPA+DHA in the cell membrane and a marker of both cell structure, health and disease risk; the omega-3 to 6 ratio. Using a scientifically validated method we are then able to determine your client’s ideal daily omega-3 intake to raise these biomarkers to levels considered optimal for health. This equation uses current body weight with existing omega-3 status, which is proven to be the most important predictor of response to omega-3 intake.
BUT….dose alone does not win the race!
In order for an omega-3 intervention to be clinically successful, the ability of the body to utilise the EPA and DHA within an oil is also of paramount importance. This is heavily influenced by both the concentration of the active ingredient in the oil and the bioavailability of the form of omega-3 the supplement contains.
Re-esterified triglycerides (rTG) offer the best solution for both, providing high concentration oils (80-90%) as well as unprecedented bioavailability. Indeed, side by side comparison studies clearly demonstrate rTG oils containing greater than 80% active EPA and DHA consistently outshine all other forms of omega-3 in their ability to raise cellular levels and deliver health benefits. Most therapeutic companies only concentrate their oils to up to approximately 60%.
Pharmepa RESTORE and MAINTAIN provide highly concentrated, rTG, pure and high EPA oils. When used in combination with the Opti-O-3 test to determine personalised dosage, this protocol provides the most fast-acting, clinically effective and personalised intervention.
Who would benefit from RESTORE and MAINTAIN?
The RESTORE and MAINTAIN protocol is designed as a highly effective intervention for inflammatory-based illness. Anyone who is not in optimal health, and where inflammation is likely to be at the root, would benefit from taking Pharmepa RESTORE.
For those who are healthy but wish to top up dietary intake of EPA and DHA, help prevent illness later in life, or as a follow-on from Pharmepa RESTORE (once symptoms have reduced), may wish to simply use Pharmepa MAINTAIN long term. For some people, long-term, high dose EPA may be necessary to support chronic conditions. It is perfectly safe to take EPA long term but we encourage the consumption of oily fish in addition to pure EPA use.
Easy manipulations for bespoke omega-3 support
In addition to split dosing for its absorption benefits, small easy to swallow capsules offer the ability to easily manipulate and adapt the types of fats being consumed according to biomarker levels, diet and lifestyle.
If someone has a poor AA to EPA ratio, for example, but their omega-3 index lies within a healthy range, then the primary focus should be on EPA restoration with Pharmepa RESTORE. If, however, someone has a reasonable AA to EPA ratio but a poor omega-3 index, it may be useful to reduce their time on pure EPA (RESTORE)and introduce DHA with the use of Pharmepa MAINTAIN, either alone or in combination with RESTORE to support cellular structure whilst still optimising EPA levels. Achieving the correct dose and the right split between EPA and DHA is easily achievable with RESTORE and MAINTAIN, and our nutrition scientists are available to help you interpret your clients’ biomarkers and product recommendations according to their unique needs, so please feel free to get in touch!
General dosing guides for those who can’t test
For some people, testing might not be possible and so we would recommend starting with a minimum dose according to the latest research into the condition they are aiming to address.